BACKGROUND: Phambili, the Merck (MRK)-Adenovirus Type 5 (Ad5) HIV-1 gag/pol/nef subtype B vaccine study, conducted in South Africa, suspended enrollment and vaccination when companion study, Step, was found non-efficacious. Although the vaccine did not prevent HIV-1 infection or lower viral-load setpoint, immune responses recognized clades B and C HIV-1 subtypes. We investigated predictors of the vaccine-induced antigen-specific immune responses. METHODS: Vaccine-induced immunogenicity was ascertained by interferon-γ ELISpot assays on the first 186 enrolled participants receiving two vaccinations. Analyses, stratified by study arm/sex, were performed on baseline demographics [sex, age, Body Mass Index (BMI), site, Adenovirus Type-5 (Ad5) ti...
Three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have tested recombinant...
Based on the partial efficacy of the HIV/AIDS Thai trial (RV144) with a canarypox vector prime and p...
Understanding the factors involved in the development of broadly neutralizing antibody (bNAb) respon...
Phambili, the Merck (MRK)-Adenovirus Type 5 (Ad5) HIV-1 gag/pol/nef subtype B vaccine study, conduct...
Phambili, the Merck (MRK)-Adenovirus Type 5 (Ad5) HIV-1 gag/pol/nef subtype B vaccine study, conduct...
Understanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV...
Background. The MRKAd5 HIV-1 gag/pol/nef subtype B vaccine was designed to elicit T-cell-mediated im...
BACKGROUND: The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and eff...
BACKGROUND: The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and eff...
Author Summary Understanding how HIV-1-broadly neutralizing antibodies (bnAbs) develop during natura...
Elevated risk of HIV-1 infection among recipients of an adenovirus serotype 5 (Ad5)-vectored HIV-1 v...
<div><p>Background</p><p>Elevated risk of HIV-1 infection among recipients of an adenovirus serotype...
Background In the Step Study, the MRKAd5 HIV-1 gag/pol/nef vaccine did not reduce plasma viraemia af...
Understanding how human genetic variation impacts individual response to immunogens is fundamental f...
Although the HVTN 505 DNA/recombinant adenovirus type 5 vector HIV-1 vaccine trial showed no overall...
Three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have tested recombinant...
Based on the partial efficacy of the HIV/AIDS Thai trial (RV144) with a canarypox vector prime and p...
Understanding the factors involved in the development of broadly neutralizing antibody (bNAb) respon...
Phambili, the Merck (MRK)-Adenovirus Type 5 (Ad5) HIV-1 gag/pol/nef subtype B vaccine study, conduct...
Phambili, the Merck (MRK)-Adenovirus Type 5 (Ad5) HIV-1 gag/pol/nef subtype B vaccine study, conduct...
Understanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV...
Background. The MRKAd5 HIV-1 gag/pol/nef subtype B vaccine was designed to elicit T-cell-mediated im...
BACKGROUND: The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and eff...
BACKGROUND: The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and eff...
Author Summary Understanding how HIV-1-broadly neutralizing antibodies (bnAbs) develop during natura...
Elevated risk of HIV-1 infection among recipients of an adenovirus serotype 5 (Ad5)-vectored HIV-1 v...
<div><p>Background</p><p>Elevated risk of HIV-1 infection among recipients of an adenovirus serotype...
Background In the Step Study, the MRKAd5 HIV-1 gag/pol/nef vaccine did not reduce plasma viraemia af...
Understanding how human genetic variation impacts individual response to immunogens is fundamental f...
Although the HVTN 505 DNA/recombinant adenovirus type 5 vector HIV-1 vaccine trial showed no overall...
Three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have tested recombinant...
Based on the partial efficacy of the HIV/AIDS Thai trial (RV144) with a canarypox vector prime and p...
Understanding the factors involved in the development of broadly neutralizing antibody (bNAb) respon...